Lexicon Pharmaceuticals (LXRX) Shares Outstanding (Weighted Average) (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $400.2 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 10.54% year-over-year to $400.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $400.2 million (up 10.54% YoY) and the FY2025 annual result came in at $363.1 million, up 13.44% from the prior year.
• Shares Outstanding (Weighted Average) improved to $400.2 million in Q1 2026 per LXRX's latest filing, from $363.1 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $400.2 million in Q1 2026 and bottomed at $183824.0 in Q2 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $245.4 million (2024), against an average of $233.2 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) plunged 99.88%; it then soared 173996.42% in 2024.
• Tracing LXRX's Shares Outstanding (Weighted Average) over 5 years: stood at $224128.0 in 2022, then decreased by 17.98% to $183824.0 in 2023, then soared by 173996.42% to $320.0 million in 2024, then gained by 13.44% to $363.1 million in 2025, then climbed by 10.24% to $400.2 million in 2026.
• Per Business Quant, the three latest LXRX Shares Outstanding (Weighted Average) figures stand at $400.2 million (Q1 2026), $363.1 million (Q4 2025), and $363.4 million (Q3 2025).

Peer Comparison